Article info
PDFEditorial
Phase I oncology trials: why the therapeutic misconception will not go away
- Correspondence to: W Glannon Departments of Philosophy and Community Health Sciences, University of Calgary, 2500 University Drive NW, Calgary, AB, T2N 1N4, Canada; wglannon{at}ucalgary.ca
Citation
Phase I oncology trials: why the therapeutic misconception will not go away
Publication history
- Received December 16, 2005
- Accepted February 23, 2006
- Revised February 20, 2006
- First published April 28, 2006.
Online issue publication
April 27, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2006 by the Journal of Medical Ethics
Other content recommended for you
- Two concepts of therapeutic optimism
- Phase 1 oncology trials and informed consent
- Therapeutic appropriation: a new concept in the ethics of clinical research
- Donor-funded research: permissible, not perfect
- Are positive experiences of children in non-therapeutic research justifiable research benefits?
- Engaging African ancestry participants in SLE clinical trials
- Subjects’ views of obligations to ensure post-trial access to drugs, care and information: qualitative results from the Experiences of Participants in Clinical Trials (EPIC) study
- Vulnerability, therapeutic misconception and informed consent: is there a need for special treatment of pregnant women in fetus-regarding clinical trials?
- Therapeutic optimism in the consent forms of phase 1 gene transfer trials: an empirical analysis
- Informed consent as an ethical requirement in clinical trials: an old, but still unresolved issue. An observational study to evaluate patient's informed consent comprehension